Clinical Trial Update: PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients

View source ↗

Summary

This clinical trial update discusses how osimertinib treatment in advanced non-small cell lung cancer influences PD-L1 and other immuno-markers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Small Cell Lung Cancer, Polygonal Type | Status: UNKNOWN